Skip to main content

Advertisement

SpringerLink
Log in

Association of microbiota with cancer treatment

  • Invited Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

The impact of immune checkpoint molecule inhibitors on cancer treatment is significant. At the same time, further improvement in their efficacy has become essential. For this reason, there has been increasing interest in investigating the state of the cancer microenvironment in which efficacy can be demonstrated. The gut microbiota plays an important role in the cancer microenvironment. Recent developments in the study of gut microbiota have been explosive, benefiting from technological innovations in next-generation sequencing. Gut microbiota are specific enough to identify an individual and change gently with age. Disruptions in the gut microbiota have been extensively studied in relation to a variety of diseases. In addition to monotherapy with anti-PD-1/PD-L1 antibodies, combination therapy with chemotherapy and molecular target therapy, as well as combination therapy with anti-PD-1 and anti-CTLA-4 antibodies, is now widely used in cancer treatment with immune checkpoint inhibitors. Therefore, the development of biomarkers that can predict anti-tumor and adverse events is urgently required due to the complexity of the treatment, and research on gut microbiota is expected in this respect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cani PD (2017) Gut microbiota-at the intersection of everything? Nat Rev Gastroenterol Hepatol 14:321–322. https://doi.org/10.1038/nrgastro.2017.54

    Article  PubMed  Google Scholar 

  2. Arboleya S et al (2012) Establishment and development of intestinal microbiota in preterm neonates. FEMS Microbiol Ecol 79:763–772. https://doi.org/10.1111/j.1574-6941.2011.01261.x

    Article  CAS  PubMed  Google Scholar 

  3. Backhed F et al (2015) Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17:852. https://doi.org/10.1016/j.chom.2015.05.012

    Article  CAS  PubMed  Google Scholar 

  4. Gopalakrishnan V et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97–103. https://doi.org/10.1126/science.aan4236

    Article  CAS  PubMed  Google Scholar 

  5. Routy B et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91–97. https://doi.org/10.1126/science.aan3706

    Article  CAS  PubMed  Google Scholar 

  6. Gevers D et al (2014) The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15:382–392. https://doi.org/10.1016/j.chom.2014.02.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ahn J et al (2013) Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 105:1907–1911. https://doi.org/10.1093/jnci/djt300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lepage P et al (2011) Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141:227–236. https://doi.org/10.1053/j.gastro.2011.04.011

    Article  PubMed  Google Scholar 

  9. Matson V et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359:104–108. https://doi.org/10.1126/science.aao3290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Dubin K et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391. https://doi.org/10.1038/ncomms10391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mao J, Wang D, Long J et al (2021) Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-003334

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ribas A (2012) Tumor immunotherapy directed at PD-1. N Engl J Med 366:2517–2519. https://doi.org/10.1056/NEJMe1205943

    Article  CAS  PubMed  Google Scholar 

  13. Qureshi OS et al (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600–603. https://doi.org/10.1126/science.1202947

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Soskic B, Qureshi OS, Hou T et al (2014) A transendocytosis perspective on the CD28/CTLA-4 pathway. Adv Immunol 124:95–136. https://doi.org/10.1016/B978-0-12-800147-9.00004-2

    Article  PubMed  Google Scholar 

  15. Vetizou M et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079–1084. https://doi.org/10.1126/science.aad1329

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sivan A et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:1084–1089. https://doi.org/10.1126/science.aac4255

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang Y et al (2018) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24:1804–1808. https://doi.org/10.1038/s41591-018-0238-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13:800–812. https://doi.org/10.1038/nrc3610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Derosa L et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29:1437–1444. https://doi.org/10.1093/annonc/mdy103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hamada K et al (2021) Antibiotic usage reduced overall survival by over 70% in non-small cell lung cancer patients on anti-PD-1 immunotherapy. Anticancer Res 41:4985–4993. https://doi.org/10.21873/anticanres.15312

    Article  CAS  PubMed  Google Scholar 

  21. Sun M, Wu W, Liu Z et al (2017) Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol 52:1–8. https://doi.org/10.1007/s00535-016-1242-9

    Article  CAS  PubMed  Google Scholar 

  22. Skelly AN, Sato Y, Kearney S et al (2019) Mining the microbiota for microbial and metabolite-based immunotherapies. Nat Rev Immunol 19:305–323. https://doi.org/10.1038/s41577-019-0144-5

    Article  CAS  PubMed  Google Scholar 

  23. Coutzac C et al (2020) Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun 11:2168. https://doi.org/10.1038/s41467-020-16079-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Reck M, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2 year update. ESMO Open 6:100273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sakai K, Sakurai T, De Velasco MA et al (2021) Intestinal microbiota and gene expression reveal similarity and dissimilarity between immune-mediated colitis and ulcerative colitis. Front Oncol 11:763468

    Article  PubMed  PubMed Central  Google Scholar 

  26. Davar D et al (2021) Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371:595–602. https://doi.org/10.1126/science.abf3363

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Baruch et al (2021) Fecal microbiota transplant promotes response in immunotherapy refractory melanoma patients. Science 371:602–609

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing.

Author information

Authors and Affiliations

  1. Division of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kitakarasuyama, Setagaya-ku, Tokyo, Japan

    Kiyoshi Yoshimura

  2. Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

    Kiyoshi Yoshimura

Authors
  1. Kiyoshi Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiyoshi Yoshimura.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshimura, K. Association of microbiota with cancer treatment. Int J Clin Oncol 28, 341–346 (2023). https://doi.org/10.1007/s10147-023-02302-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-023-02302-4

Keywords

Search

Navigation